Aeterna Zentaris (TSE:AEZS) Stock Price Down 38.5% – What’s Next?

Aeterna Zentaris Inc. (TSE:AEZS)’s share price fell 38.5% during mid-day trading on Monday . The company traded as low as C$5.10 and last traded at C$5.10. 286 shares changed hands during mid-day trading, a decline of 75% from the average session volume of 1,137 shares. The stock had previously closed at C$8.29.

Aeterna Zentaris Stock Down 38.5 %

The company has a market capitalization of C$15.61 million, a PE ratio of -1.60 and a beta of 2.26. The company has a debt-to-equity ratio of 1.80, a quick ratio of 9.37 and a current ratio of 5.94. The stock’s 50 day moving average is C$5.65 and its 200 day moving average is C$7.35.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.